CASP3 and Hepatic fibrosis: In line with the reduction of liver fibrosis and steatosis, caspase-3 activity was decreased in liver tissues from Atrosab- and Atrosimab-treated NASH mice, compared to saline-treated mice (Figures 6E, F).